3,084,166 Shares in Solventum Co. (NYSE:SOLV) Acquired by Norges Bank

Norges Bank acquired a new stake in shares of Solventum Co. (NYSE:SOLV) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,084,166 shares of the company’s stock, valued at approximately $203,740,000.

Several other large investors have also recently bought and sold shares of the company. Modus Advisors LLC acquired a new position in shares of Solventum in the 4th quarter valued at $25,000. Stonebridge Financial Group LLC bought a new position in Solventum during the fourth quarter worth about $26,000. True Wealth Design LLC increased its holdings in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after acquiring an additional 471 shares in the last quarter. Crews Bank & Trust acquired a new stake in shares of Solventum during the fourth quarter worth about $32,000. Finally, Synergy Asset Management LLC acquired a new position in shares of Solventum in the 4th quarter valued at approximately $35,000.

Solventum Stock Down 1.0 %

NYSE:SOLV opened at $74.78 on Monday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The firm has a market capitalization of $12.94 billion and a price-to-earnings ratio of 27.19. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock’s 50 day moving average price is $75.51 and its two-hundred day moving average price is $71.87.

Analysts Set New Price Targets

SOLV has been the topic of a number of research reports. Piper Sandler lifted their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. The Goldman Sachs Group upped their price objective on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Bank of America lifted their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Finally, Mizuho boosted their target price on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.